TORONTO, April 8, 2025 /PRNewswire/ -- MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for rapid bacterial detection in wounds, announces its presence at the American Burn Association (ABA) Annual Meeting in Phoenix, AZ, April 8-11. MolecuLight will showcase its innovative fluorescence imaging systems that empower providers with immediate, non-invasive bacterial visualization for optimized burn care.
Attendees at the ABA meeting will have the opportunity to:
ththndth"The ability to visualize bacteria in real-time with MolecuLight has far-reaching implications for improving burn wound reconstruction," says Dr. Erik Hanson-Viana. "By providing immediate, actionable information, MolecuLight has led to more precise interventions, ultimately improving reconstructive outcomes. My research also demonstrates the clear advantage of MolecuLight-targeted sampling over traditional methods, and I am thrilled to share these findings with my colleagues at the ABA meeting."
About MolecuLight Inc:
MolecuLight Inc. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.
Comunicato stampa - Responsabilità editoriale PrNewswire
